Technavio

Discover Market Opportunities

Emergence of HBV and HCV-specific immunosensors to boost growth in the hepatitis B and C diagnostics market

Renewable energy

 

Hepatitis B and C diagnostics: Key market research findings

  • The Americas dominate the market geographically
  • Hepatitis C segment accounts for a majority of the market’s revenue
  • Key vendors – Roche Diagnostics, Abbott, Siemens, and Qiagen

Technavio’s market research analysts predict the global hepatitis B and C diagnostics market to grow at a CAGR of around 6% between 2016 and 2020. The market is driven primarily by the growing demand for molecular diagnostics in the diagnosis of HBV and HCV infections. The popular applications for molecular diagnostics include identification and profiling of causative agents of infection, and quantification of pathogens to monitor durability of therapy. Currently, the sales of molecular diagnostics for infectious diseases such as HBV and HCV generate approximately 60% of overall molecular diagnostics market. During 2015, the global hepatitis B and C diagnostics market was dominated by the Americas during 2015 by accounting for more than 48% of the overall market revenue. The emergence of the POC tests is expected to drive the market growth in the Americas over the next four years.

The new market research report from Technavio presents a breakdown and analysis of the hepatitis B and C diagnostics segments based on the disease.

“The emergence of immunosensors in the application of HBV and HCV diagnosis is expected to augment the market’s growth in the coming years. The increasing need for improved diagnosis has resulted in the development of immunosensors. The biosensor technology enables more accurate anti-HCV and HCV RNA detection. These devices transform specific antibody-antigen interactions into measurable piezoelectric, acoustic, electrochemical, magnetic, or optical signals,” says Barath Palada, Lead Analyst, Healthcare & Lifesciences, Technavio Research.

In 2015, the hepatitis C segment accounted for around 90% of the overall market revenue to become the dominant shareholder in the global market. The disease is prevalent in North America, Africa, the Middle East, and Central and East Asia. The emergence of third-generation anti-HCV immunoassay tests drives the market owing to its higher sensitivity when compared to second-generation tests. Furthermore, the presence of high under-diagnosed individuals particularly in low- and middle-income countries presents high growth opportunities in the hepatitis C diagnostics market.

The key vendors in the global hepatitis B and C diagnostics market include Roche Diagnostics, Abbott, Siemens, and Qiagen. Roche Diagnostics is pursuing aggressive R&D activities to develop new diagnostic tests. For instance, in March 2015, Abbott Diagnostics received an approval from the US FDA for ARCHITECT CORE, an automated hepatitis B test diagnosis to be used as an aid in the diagnosis of HCV infection in specific groups. In November 2015, Roche Diagnostics launched rapid tests for hepatitis C and hep C genotyping in Europe, solidifying its presence in molecular diagnostics-related tests. QIAGEN is the nearest competitor to the Roche Diagnostics. Particularly, it has a strong position in the molecular diagnostics segment. QIAGEN is collaborating with other companies to develop new diagnostic tests.

A more detailed analysis is available in the Technavio report, Global Hepatitis B and C Diagnostics Market 2016-2020.

We can customize reports by other regions and specific segments upon request.

Other related reports:

Related News